Evidence map›Paper›PMID 19920114›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2009

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.

Evan Y Yu, George Wilding, Edwin Posadas, Mitchell Gross, Stephane Culine, Christophe Massard, Michael J Morris, Gary Hudes, Fabio Calabrò, Shinta Cheng and 3 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00385580 (Phase II Study of Dasatinib), which is not on this map. Cited by 109 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 2 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00385580 phase2completednot on this map

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

TypeinterventionalSponsorBristol-Myers SquibbRan2007 to 2010Enrolled94ConditionsProstate CancerArmsdasatinib
3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 2 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Review
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Evan Y YuUniversity of Washington, Seattle, Washington, USA.
George Wilding
Edwin Posadas
Mitchell Gross
Stephane Culine
Christophe Massard
Michael J Morris
Gary Hudes
Fabio Calabrò
Shinta Cheng
Géralyn C Trudel
Prashni Paliwal
Cora N Sternberg
Memorial Sloan Kettering Cancer Center · USBristol-Myers Squibb (United States) · USUniversity of Chicago · USCarlo Forlanini Hospital · ITCEA Valduc · FRInstitut Gustave Roussy · FRUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
NCI NIH HHS P30 CA014520
6 · The paper itself

Abstract

purposeAntiproliferative and antiosteoclastic activity from preclinical models show potential for dasatinib, an oral SRC and SRC family kinase inhibitor, as a targeted therapy for patients with prostate cancer. This phase II study investigated the activity of dasatinib in patients with metastatic castration-resistant prostate cancer (CRPC). EXPERIMENTAL

designChemotherapy-naive men with CRPC and increasing prostate-specific antigen were treated with dasatinib 100 or 70 mg twice daily. Endpoints included changes in prostate-specific antigen, bone scans, measurable disease (Response Evaluation Criteria in Solid Tumor), and markers of bone metabolism. Following Prostate Cancer Working Group 2 guidelines, lack of progression according to Response Evaluation Criteria in Solid Tumor and bone scan was determined and reported at 12 and 24 weeks.

resultsForty-seven patients were enrolled and received dasatinib (initial dose 100 mg twice daily, n = 25; 70 mg twice daily, n = 22), of whom 41 (87%) had bone disease. Lack of progression was achieved in 20 (43%) patients at week 12 and in 9 (19%) patients at week 24. Of 41 evaluable patients, 21 (51%) patients achieved > or =40% reduction in urinary N-telopeptide by week 12, with 33 (80%) achieving some level of reduction anytime on study. Of 15 patients with elevated urinary N-telopeptide at baseline, 8 (53%) normalized on study. Of 40 evaluable patients, 24 (60%) had reduction in bone alkaline phosphatase at week 12 and 25 (63%) achieved some reduction on study. Dasatinib was generally well tolerated and treatment-related adverse events were moderate.

conclusionsThis study provides encouraging evidence of dasatinib activity in bone and reasonable tolerability in chemotherapy-naive patients with metastatic CRPC.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsCell ProliferationDasatinibDisease ProgressionHumansMaleMiddle AgedNeoplasm MetastasisOrchiectomyProstate-Specific AntigenProstatic NeoplasmsProtein Kinase InhibitorsPyrimidinesThiazolesAntineoplastic AgentsDasatinibProstate-Specific AntigenProtein Kinase InhibitorsPyrimidinesThiazoles

Identifiers

PMID19920114
PMCPMC3394097
OpenAlexW2118263555

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.